

David Irwin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5076396/publications.pdf>

Version: 2024-02-01

228
papers

14,282
citations

26610

56
h-index

24961

109
g-index

251
all docs

251
docs citations

251
times ranked

12518
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
2	Stages of pTDP ⁴³ pathology in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2013, 74, 20-38.	2.8	820
3	Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. <i>Nature Reviews Neuroscience</i> , 2013, 14, 626-636.	4.9	673
4	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
5	Neuropathologic substrates of Parkinson disease dementia. <i>Annals of Neurology</i> , 2012, 72, 587-598.	2.8	401
6	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	4.9	394
7	Association of Cerebrospinal Fluid β -Amyloid 1-42, T-tau, P-tau ₁₈₁ , and α -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 1277-87.	4.5	318
8	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. <i>JAMA Neurology</i> , 2013, 70, 223.	4.5	302
9	SpaGCN: Integrating gene expression, spatial location and histology to identify spatial domains and spatially variable genes by graph convolutional network. <i>Nature Methods</i> , 2021, 18, 1342-1351.	9.0	291
10	Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829.	4.5	244
11	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). <i>Acta Neuropathologica</i> , 2014, 127, 423-439.	3.9	237
12	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. <i>Brain</i> , 2012, 135, 807-818.	3.7	226
13	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. <i>Acta Neuropathologica</i> , 2015, 129, 469-491.	3.9	218
14	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	3.9	210
15	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. <i>Acta Neuropathologica</i> , 2014, 128, 423-437.	3.9	203
16	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
17	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
18	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.4	167

#	ARTICLE	IF	CITATIONS
19	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. <i>Acta Neuropathologica</i> , 2012, 123, 825-839.	3.9	164
20	Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. <i>Acta Neuropathologica</i> , 2017, 134, 65-78.	3.9	163
21	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	4.5	161
22	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. <i>Acta Neuropathologica</i> , 2014, 128, 525-541.	3.9	154
23	Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone. <i>JAMA Neurology</i> , 2013, 70, 462.	4.5	153
24	Tauopathies as clinicopathological entities. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S29-S33.	1.1	148
25	Deep clinical and neuropathological phenotyping of <sc>P</sc>ick disease. <i>Annals of Neurology</i> , 2016, 79, 272-287.	2.8	146
26	Cognitive decline and reduced survival in <i>C9orf72</i> expansion frontotemporal degeneration and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 163-169.	0.9	141
27	Prevalence of amyloidâ€² pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
28	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 89.	3.0	129
29	Differentiating primary progressive aphasias in a brief sample of connected speech. <i>Neurology</i> , 2013, 81, 329-336.	1.5	126
30	Pathological ð±-synuclein distribution in subjects with coincident Alzheimerâ€™s and Lewy body pathology. <i>Acta Neuropathologica</i> , 2016, 131, 393-409.	3.9	123
31	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
32	Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. <i>Neurology</i> , 2017, 88, 2276-2284.	1.5	114
33	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
34	Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. <i>Acta Neuropathologica</i> , 2015, 129, 39-52.	3.9	111
35	Development and Validation of Pedigree Classification Criteria for Frontotemporal Lobar Degeneration. <i>JAMA Neurology</i> , 2013, 70, 1411.	4.5	107
36	Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies. <i>American Journal of Pathology</i> , 2013, 183, 344-351.	1.9	104

#	ARTICLE	IF	CITATIONS
37	Comparison of Cerebrospinal Fluid Levels of Tau and A β 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. <i>Archives of Neurology</i> , 2012, 69, 1018-25.	4.9	100
38	Evaluating the Patterns of Aging-Related Tau Astroglial Pathology Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 270-288.	0.9	98
39	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
40	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
41	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
42	Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
43	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	2.8	88
44	Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau. <i>Science</i> , 2020, 370, .	6.0	85
45	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 949-955.	0.9	82
46	Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 935-937.	3.9	81
47	Utility of the global CDR [®] plus NACC FTLTDP rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, 106-117.	0.4	81
48	The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. , 2018, 08, .		80
49	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 6.	1.7	79
50	Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. <i>Brain and Language</i> , 2013, 127, 106-120.	0.8	77
51	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 442.	4.5	74
52	Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. <i>Brain</i> , 2020, 143, 191-209.	3.7	74
53	Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 216-228.	0.9	69
54	CSF tau and A β predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018, 90, e1038-e1046.	1.5	68

#	ARTICLE	IF	CITATIONS
55	<i>C9orf72</i> promoter hypermethylation is neuroprotective. <i>Neurology</i> , 2015, 84, 1622-1630.	1.5	66
56	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. <i>Acta Neuropathologica</i> , 2015, 130, 363-372.	3.9	65
57	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 2945-2950.	2.2	63
58	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 75-87.	1.5	61
59	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. <i>Movement Disorders</i> , 2020, 35, 5-19.	2.2	60
60	Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 691-708.	1.9	59
61	Apathy in Frontotemporal Degeneration: Neuroanatomical Evidence of Impaired Goal-directed Behavior. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 611.	1.0	57
62	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. <i>Brain</i> , 2018, 141, 288-301.	3.7	56
63	An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. <i>Nature Communications</i> , 2020, 11, 5522.	5.8	56
64	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	2.8	55
65	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> , 2018, 75, 738.	4.5	54
66	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019, 85, 801-811.	2.8	52
67	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
68	Deficits in sentence expression in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 31-39.	1.1	51
69	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017, 82, 247-258.	2.8	51
70	Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease. <i>Brain</i> , 2020, 143, 1572-1587.	3.7	50
71	Comparative semantic profiles in semantic dementia and Alzheimer's disease. <i>Brain</i> , 2013, 136, 2497-2509.	3.7	47
72	Grammatical comprehension deficits in non-fluent/agrammatic primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 249-256.	0.9	46

#	ARTICLE	IF	CITATIONS
73	Automatic measurement of prosody in behavioral variant FTD. <i>Neurology</i> , 2017, 89, 650-656.	1.5	46
74	Validated automatic speech biomarkers in primary progressive aphasia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 4-14.	1.7	45
75	Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 315-329.	1.8	44
76	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2014, 35, 1473-1482.	1.5	43
77	Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 54-66.	1.3	43
78	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	0.8	43
79	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. <i>Alzheimer's and Dementia</i> , 2020, 16, 118-130.	0.4	43
80	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 843-852.	0.4	43
81	Narrative discourse deficits in amyotrophic lateral sclerosis. <i>Neurology</i> , 2014, 83, 520-528.	1.5	40
82	Cognitive reserve in frontotemporal degeneration. <i>Neurology</i> , 2016, 87, 1813-1819.	1.5	40
83	Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. <i>Annals of Neurology</i> , 2019, 85, 630-643.	2.8	40
84	Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. <i>Neurology</i> , 2017, 89, 1604-1611.	1.5	39
85	Multisite Assessment of Aging-Related Tau Astroglial Pathology (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	0.9	38
86	Neural Correlates of Verbal Episodic Memory and Lexical Retrieval in Logopenic Variant Primary Progressive Aphasia. <i>Frontiers in Neuroscience</i> , 2017, 11, 330.	1.4	38
87	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
88	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. <i>Brain</i> , 2021, 144, 2784-2797.	3.7	38
89	Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 149-154.	0.9	37
90	Longitudinal progression of grey matter atrophy in non-amnesic Alzheimer's disease. <i>Brain</i> , 2019, 142, 1701-1722.	3.7	37

#	ARTICLE	IF	CITATIONS
91	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
92	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 296-304.	0.9	35
93	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. <i>Acta Neuropathologica Communications</i> , 2017, 5, 68.	2.4	34
94	Cerebrospinal fluid Î±â€synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
95	A longitudinal study of speech production in primary progressive aphasia and behavioral variant frontotemporal dementia. <i>Brain and Language</i> , 2019, 194, 46-57.	0.8	34
96	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	5.8	34
97	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
98	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. <i>Alzheimer's and Dementia</i> , 2020, 16, 22-36.	0.4	32
99	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 137.	3.0	32
100	Emerging Diagnostic and Therapeutic Strategies for Tauopathies. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 72.	2.0	31
101	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2019, 73, 190-199.	1.5	31
102	Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration. <i>Neurology</i> , 2015, 84, 2070-2075.	1.5	30
103	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	3.9	29
104	Dissociable substrates underlie the production of abstract and concrete nouns. <i>Brain and Language</i> , 2017, 165, 45-54.	0.8	28
105	Cognitive Profile and Markers of Alzheimer Diseaseâ€Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021, 96, e1855-e1864.	1.5	28
106	Detection of Alzheimerâ€™s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). <i>Acta Neuropathologica Communications</i> , 2019, 7, 34.	2.4	27
107	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.4	27
108	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, 822-830.	0.4	27

#	ARTICLE	IF	CITATIONS
109	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. <i>Neurology</i> , 2014, 83, 502-509.	1.5	26
110	A comparison of A β 2 amyloid pathology staging systems and correlation with clinical diagnosis. <i>Acta Neuropathologica</i> , 2014, 128, 543-550.	3.9	26
111	Getting on the same page: The neural basis for social coordination deficits in behavioral variant frontotemporal degeneration. <i>Neuropsychologia</i> , 2015, 69, 56-66.	0.7	26
112	Converging Patterns of α -Synuclein Pathology in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1005-1016.	0.9	26
113	Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. <i>Acta Neuropathologica Communications</i> , 2014, 2, 33.	2.4	25
114	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. <i>Neurology</i> , 2016, 87, 1227-1234.	1.5	25
115	ATN status in amnesic and non-amnesic Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain</i> , 2020, 143, 2295-2311.	3.7	24
116	Defining and predicting transdiagnostic categories of neurodegenerative disease. <i>Nature Biomedical Engineering</i> , 2020, 4, 787-800.	11.6	22
117	Clinical Conditions "Suggestive of Progressive Supranuclear Palsy" Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	2.2	22
118	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 30.	2.4	22
119	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	2.2	22
120	Tau immunotherapy is associated with glial responses in FTLD-tau. <i>Acta Neuropathologica</i> , 2021, 142, 243-257.	3.9	22
121	Can MRI screen for CSF biomarkers in neurodegenerative disease?. <i>Neurology</i> , 2013, 80, 132-138.	1.5	21
122	Dissociation of quantifiers and object nouns in speech in focal neurodegenerative disease. <i>Neuropsychologia</i> , 2016, 89, 141-152.	0.7	21
123	Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 19, 497-506.	1.4	21
124	Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 707-721.	1.8	21
125	Brain volumetric deficits in MAPT mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
126	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. <i>Cell Reports Medicine</i> , 2022, 3, 100607.	3.3	21

#	ARTICLE	IF	CITATIONS
127	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from \pm -Synucleinopathies. <i>Radiology</i> , 2019, 293, 646-653.	3.6	20
128	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	1.7	20
129	Estimating frontal and parietal involvement in cognitive estimation: a study of focal neurodegenerative diseases. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 317.	1.0	19
130	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	0.9	19
131	Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders. <i>Neurology</i> , 2020, 95, e1629-e1639.	1.5	19
132	Tau Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	2.8	19
133	Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration. <i>Brain Imaging and Behavior</i> , 2019, 13, 293-301.	1.1	18
134	Automated analysis of lexical features in frontotemporal degeneration. <i>Cortex</i> , 2021, 137, 215-231.	1.1	18
135	Rates of longitudinal change in >18 β -flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1235-1247.	0.4	18
136	Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 298.	1.4	17
137	Elevated YKL-40 and low sAPP β :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	0.9	17
138	The Accumulation of Tau-Immunoreactive Hippocampal Granules and Corpora Amylacea Implicates Reactive Glia in Tau Pathogenesis during Aging. <i>iScience</i> , 2020, 23, 101255.	1.9	17
139	Dimethyl Fumarate, an Approved Multiple Sclerosis Treatment, Reduces Brain Oxidative Stress in SIV-Infected Rhesus Macaques: Potential Therapeutic Repurposing for HIV Neuroprotection. <i>Antioxidants</i> , 2021, 10, 416.	2.2	17
140	Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology. <i>NeuroImage: Clinical</i> , 2022, 33, 102913.	1.4	17
141	Primary Progressive Aphasia and Stroke Aphasia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 745-767.	0.4	16
142	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. <i>Acta Neuropathologica</i> , 2020, 140, 675-693.	3.9	15
143	The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease. <i>Brain</i> , 2022, 145, 324-339.	3.7	15
144	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14

#	ARTICLE	IF	CITATIONS
145	Multimodal inÂvivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020, 96, 137-147.	1.5	14
146	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 173.	2.4	14
147	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 682.	1.4	13
148	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e12595.	3.3	13
149	Quantitative detection of Î±-Synuclein and Tau oligomers and other aggregates by digital single particle counting. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	13
150	The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research. <i>Psychiatric Clinics of North America</i> , 2015, 38, 309-322.	0.7	12
151	Beyond words: Pragmatic inference in behavioral variant of frontotemporal degeneration. <i>Neuropsychologia</i> , 2015, 75, 556-564.	0.7	12
152	Tauopathy with hippocampal 4â€repeat tau immunoreactive spherical inclusions: a report of three cases. <i>Brain Pathology</i> , 2018, 28, 274-283.	2.1	12
153	Nonlinear Zâ€score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 797-808.	1.2	12
154	Digital Speech Analysis in Progressive Supranuclear Palsy and Corticobasal Syndromes. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 33-45.	1.2	12
155	Downstream effects of poly pathology on neurodegeneration of medial temporal lobe subregions. <i>Acta Neuropathologica Communications</i> , 2021, 9, 128.	2.4	12
156	The Mental Status Examination in Patients With Suspected Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 385-403.	0.4	12
157	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
158	Signature laminar distributions of pathology in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 143, 363-382.	3.9	12
159	Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies. <i>Neurobiology of Aging</i> , 2018, 68, 85-92.	1.5	11
160	Genetic predictors of survival in behavioral variant frontotemporal degeneration. <i>Neurology</i> , 2019, 93, e1707-e1714.	1.5	11
161	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 1115-1124.	0.4	11
162	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 183-193.	0.6	10

#	ARTICLE	IF	CITATIONS
163	Lexical and Acoustic Characteristics of Young and Older Healthy Adults. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 302-314.	0.7	10
164	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23.	3.0	9
165	Regional Brain Recovery from Acute Synaptic Injury in Simian Immunodeficiency Virus-Infected Rhesus Macaques Associates with Heme Oxygenase Isoform Expression. <i>Journal of Virology</i> , 2020, 94, .	1.5	9
166	Outcome Measures for Dementia With Lewy Body Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2021, Publish Ahead of Print, .	0.6	9
167	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1155-1167.	1.5	9
168	Acalculia in Autopsy-Proven Corticobasal Degeneration. <i>Neurology</i> , 2011, 76, S61-3.	1.5	8
169	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 103, 158.e1-158.e5.	1.5	8
170	Biomarker Use for Dementia With Lewy Body Diagnosis. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 55-61.	0.6	8
171	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017, 11, 53.	1.4	7
172	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	4.4	7
173	3D Mapping of TAU Neurofibrillary Tangle Pathology in the Human Medial Temporal Lobe. , 2020, , .		6
174	Clinical Correlates of Alzheimer's Disease Cerebrospinal Fluid Analytes in Primary Progressive Aphasia. <i>Frontiers in Neurology</i> , 2019, 10, 485.	1.1	5
175	Cross-sectional and longitudinal medial temporal lobe subregional atrophy patterns in semantic variant primary progressive aphasia. <i>Neurobiology of Aging</i> , 2021, 98, 231-241.	1.5	5
176	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021, 11, 105-116.	0.8	5
177	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology. <i>Neurobiology of Aging</i> , 2022, 113, 95-107.	1.5	5
178	Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. <i>Parkinsonism and Related Disorders</i> , 2022, 100, 33-36.	1.1	5
179	Many roads to Parkinson's disease neurodegeneration: Head trauma "A road more traveled than we know?". <i>Movement Disorders</i> , 2013, 28, 1167-1170.	2.2	4
180	Processing ambiguity in a linguistic context: decision-making difficulties in non-aphasic patients with behavioral variant frontotemporal degeneration. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 583.	1.0	4

#	ARTICLE	IF	CITATIONS
181	Longitudinal naming and repetition relates to AD pathology and burden in autopsy-confirmed primary progressive aphasia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12188.	1.8	4
182	More Than Words: Extra-Sylvian Neuroanatomic Networks Support Indirect Speech Act Comprehension and Discourse in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 598131.	1.0	4
183	Neuropathological substrates of cognition in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 177-193.	0.9	4
184	Divergent Histopathological Networks of Frontotemporal Degeneration Proteinopathy Subtypes. <i>Journal of Neuroscience</i> , 2022, 42, 3868-3877.	1.7	4
185	Complex regional pain syndrome with associated chest wall dystonia: a case report. <i>Journal of Brachial Plexus and Peripheral Nerve Injury</i> , 2014, 06, e40-e43.	1.0	3
186	Building an Ex Vivo Atlas of the Earliest Brain Regions Affected by Alzheimer's Disease Pathology. , 2020, , .		3
187	Comparison of the Iowa Reference Algorithm to the Heidelberg Spectralis optical coherence tomography segmentation algorithm. <i>Journal of Biophotonics</i> , 2020, 13, e201960187.	1.1	3
188	Hippocampal subfield pathologic Burden in Lewy body diseases versus Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 707-708.	1.8	3
189	Cognitive and Neuroanatomic Accounts of Referential Communication in Focal Dementia. <i>ENeuro</i> , 2019, 6, ENEURO.0488-18.2019.	0.9	3
190	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLT Pathological Subtypes but Correlates with Cognitive Decline in FTLT Tauopathies. <i>Biomolecules</i> , 2021, 11, 1484.	1.8	3
191	Effects of Prescribed Medications on Cognition and Behavior in Frontotemporal Lobar Degeneration. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 566-571.	0.9	2
192	Neuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 232-238.	0.6	2
193	In Vivo Detection of Underlying Synucleinopathies. <i>Neurology</i> , 2021, 96, 925-926.	1.5	2
194	Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2021, 108, 16-23.	1.5	2
195	Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLT-tau. <i>Acta Neuropathologica Communications</i> , 2021, 9, 184.	2.4	2
196	Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12294.	1.8	2
197	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1553-1566.	1.2	2
198	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2017, 10, 693.	1.0	1

#	ARTICLE	IF	CITATIONS
199	Optimized extraction of the medial temporal lobe for postmortem MRI based on custom 3D printed molds. <i>Alzheimer's and Dementia</i> , 2020, 16, e043254.	0.4	1
200	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 124.	3.0	1
201	Preparing for the age of therapeutic trials in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, , jnnp-2021-327497.	0.9	1
202	Cerebrospinal fluid neurogranin in non-amnestic and amnestic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
203	Calsyntenin-1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
204	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
205	A tribute to John Q. Trojanowski (1946-2022). <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	1
206	[P4-238]: AMNESTIC AND NON-AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE: AN MRI-BASED PHASING ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1365.	0.4	0
207	IC-06-03: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON-AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P12.	0.4	0
208	O2-14-02: THE CLINICAL SPECTRUM OF FRONTOTEMPORAL LOBAR DEGENERATION IN NORTH AMERICA: BASELINE CHARACTERISTICS OF THE FIRST 912 PARTICIPANTS FROM THE ADVANCING RESEARCH AND TREATMENT IN FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P656.	0.4	0
209	O1-08-01: THE NIH-EXAMINER IS SENSITIVE TO COGNITIVE CHANGES IN ASYMPTOMATIC AND MILDLY SYMPTOMATIC FAMILIAL FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P235.	0.4	0
210	P3-406: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON-AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1259.	0.4	0
211	O5-03-04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1646.	0.4	0
212	O4-03-01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA. <i>Alzheimer's and Dementia</i> , 2019, 15, P1234.	0.4	0
213	IC-P-143: RELATIVE SPARING OF MEDIAL TEMPORAL SUBREGION VOLUMES IN NON-AMNESTIC ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P116.	0.4	0
214	IC-P-043: CONTRIBUTION OF TAU, TDP-43, Î-AMYLOID AND Î-SYNUCLEIN TO MEDIAL TEMPORAL LOBE ATROPHY. <i>Alzheimer's and Dementia</i> , 2019, 15, P46.	0.4	0
215	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e042846.	0.4	0
216	Alzheimer disease biomarker profiles in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, 1076-1077.	1.5	0

#	ARTICLE	IF	CITATIONS
217	Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimer's disease co-pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
218	Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, e052495.	0.4	0
219	Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood. <i>Alzheimer's and Dementia</i> , 2021, 17, e050692.	0.4	0
220	Unfolding the medial temporal lobe to characterize neurodegeneration due to Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
221	Reduced longitudinal change in ¹⁸ F-flortaucipir PET is associated with clinical phenotype in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
222	Dementia with Lewy bodies (DLB) with amyloid co-pathology has a distinct CSF proteomics profile compared to pure DLB and Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
223	Investigating white matter connectomes in amnestic and non-amnestic Alzheimer's disease clinical variants. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
224	Application of histopathologically derived 3D tau burden map as in vivo region of interest for biomarker analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
225	Clinical value of CSF tau, p-tau181, neurogranin and neurofilaments in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
226	Diagnostic value of plasma p-tau217 in frontotemporal dementia spectrum disorders. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
227	Regional distribution of tau pathology in subfields of hippocampus among phenotypic variants of AD and FTLD-tau.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052392.	0.4	0
228	Mapping tau burden and neuronal loss in MAPT-associated frontotemporal lobar degeneration.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054141.	0.4	0